Clinical trials: Polycystic Kidney Disease
Polyuria, Autosomal Dominant Polycystic Kidney
Dietary Intervention in ADPKD on Tolvaptan
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD.
- Trial name
- DIAT (NCT03858439)
- Testing
- Dietary
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Autosomal Dominant Polycystic Kidney Disease
Effect of the Aquaretic Tolvaptan on Nitric Oxide System
Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which stimulates V1-receptors in the vascular bed and…
- Trial name
- TOPO (NCT02527863)
- Testing
- Tolvaptan
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Regional Hospital Holstebro
Autosomal Dominant Polycystic Kidney, ADPKD
Analysis of Patients With Autosomal Dominant Polycystic Kidney
The main objective of the study is to establish a database of clinical data and genetic data of patients diagnosed with ADPKD, with particular focus on those who have undertaken a specific therapy (Tolvaptan or Octreotide)…
- Trial name
- NCT06759142
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.
- Trial name
- NCT02616055
- Testing
- tesevatinib
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Kadmon Corporation, LLC
Autosomal Dominant Polycystic Kidney Disease
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
The Division of Kidney Urology and Hematology Disease (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) funded a cooperative agreement (UO1) for a consortium of participating clinical centers…
- Trial name
- CRISP II (NCT01039987)
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- University of Pittsburgh
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
- Trial name
- NCT07792408
- Testing
- VX-407, LNG/EE, NGM/EE
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney Disease, Glomerular Filtration Rate > 40 ml/Min
Effects of Somatostatin on ADPKD Heart
Autosomal dominant polycystic kidney disease (ADPKD) is associated with early onset hypertension and left ventricular (LV) hypertrophy.
- Trial name
- NCT02119013
- Testing
- Octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
Polycystic Kidney, Type 1 Autosomal Dominant Disease, Polycystic Kidney, Type 2 Autosomal Dominant Disease
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
Sirolimus (SIR) has lead to a reduction of overall kidney size, a decrease in cyst density and general tubular cell proliferation in animal models, and to a reduction of the increase in creatinine and blood urea nitrogen by 34…
- Trial name
- RAP (NCT02055079)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 68 people
- Sponsor
- Medical University of Vienna
ADPKD
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A mild reduction in food intake significantly inhibits renal cyst growth in mouse models of ADPKD. The underlying mechanism was unknown at the time.
- Trial name
- Keto-ADPKD (NCT04680780)
- Testing
- Ketogenic diet, 3-days water-fasting, Control
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- University of Cologne
Polycystic Liver Disease, Hepatomegaly
Lanreotide as Treatment of Polycystic Livers
To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney, Autosomal Dominant
- Trial name
- LOCKCYST (NCT00565097)
- Testing
- Lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 38 people
- Sponsor
- Radboud University Medical Center
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study
This is a no-profit, retrospective observational study involving real-world data (RWD), retrieved from ADPKD-related electronic health records stored at Mario Negri Institute IRCCS.
- Trial name
- SAILING-ADPKD (NCT07016282)
- Where
- 2 sites in Italy, Sweden
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease
Managing Depressive Symptoms in ADPKD
The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic…
- Trial name
- NCT07745920
- Testing
- Mayo Clinic-Approved Education, Digital Neuropathy, Capacity Coaching
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in ADPKD models, while triptolide-containing formulation was revealed to potentially slow the disease progression in several proteinuric ADPKD…
- Trial name
- NCT02115659
- Testing
- Triptolide-Containing Formulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Changzheng Hospital
Polycystic Ovary Syndrome
Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)
Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in circulating insulin-stimulated…
- Trial name
- PCOS (NCT00868140)
- Testing
- pioglitazone
- Where
- 2 sites in United States, Venezuela
- Volunteers
- 51 people
- Sponsor
- Virginia Commonwealth University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
The general aim of this study in adult patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and severe renal insufficiency is to assess the safety and the efficacy of sirolimus (SRL) in slowing renal function…
- Trial name
- SIRENA-II (NCT01223755)
- Testing
- Sirolimus, conventional therapy
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
ADPKD (autosomal Dominant Polycystic Kidney Disease)
Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.
- Trial name
- NCT06658964
- Testing
- Cohort 1: JMKX003142 and itraconazole, Cohort 2: JMKX003142 and rifampicin
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jemincare
ADPKD
The Vienna RAP Pilot Study
The purpose of this study is to evaluate the safety of a daily single oral dose of sirolimus in patients with advanced autosomal dominant polycystic kidney disease.
- Trial name
- RAP (NCT01632605)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital
Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital
polycystic kidney disease is aherditary disorder characterized by the formation of numerous fluid filled cysts in the kidneys which can lead to progressive renal impairment PKDencompasses aspectrum of disorders with autosomal…
- Trial name
- NCT06601829
- Testing
- abdominal ultrasound
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Polycystic Kidney
Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
Abdominal pain, sometimes severe, is a known symptom of polycystic kidney disease (PKD) related to the cystic expansion. This study will investigate whether the vasopressin V2 receptor antagonist lixivaptan can alleviate…
- Trial name
- NCT03717181
- Testing
- Lixivaptan
- Where
- United States
- Sponsor
- Palladio Biosciences
Autosomal Dominant Polycystic Kidney
GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GBP-213 in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT07891364
- Testing
- GBP-213
- Where
- China
- Volunteers
- 24 people
- Sponsor
- RenJi Hospital